CoreAge Rx vs Pallas Health
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Pallas Health head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 63 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make Pallas Health a bad call — it's best for readers who can absorb $597 in a single charge every 12 weeks and want a provider that will tell them who compounds and who prescribes — not readers budgeting a predictable monthly bill. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Pallas Health | |
|---|---|---|
| Brief Score | 94/100 (A) | 63/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | $199/mo average, compounded — but it bills $597 every 12 weeks, not monthly ($139 first 4 weeks) |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | $299/mo average, compounded — but it bills $897 every 12 weeks, not monthly ($179 first 4 weeks) |
| Coverage | US only; restrictions by state, confirmed at intake | Nationwide — all 50 states + DC |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
Pallas Health: First reading, 7 August 2026. The advertised averages are $199/mo semaglutide and $299/mo tirzepatide, but no month-to-month plan exists to buy: the charge is $139 up front, then $597 every 12 weeks from four weeks after approval ($179, then $897, on tirzepatide). Because an 84-day cycle recurs 4.35 times a year rather than four, those renewal terms work out at roughly $216 and $325 a month once the intro period is behind you.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.